Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04391803 · ClinicalTrials.gov registry record · NA
EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)
A NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04391803 is a NA study that was terminated before completion, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 25 participants.
The verdict
NCT04391803, a NA study, was terminated before completion, sponsored by Medtronic Neurovascular Clinical Affairs.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
Interventions
- DEVICE Pipeline™ Flex Embolization Device with Shield Technology™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-06 |
| Est. Completion | 2025-10-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04391803
The ClinicalTrials.gov registry entry for NCT04391803 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Neurovascular Clinical Affairs, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pipeline™ Flex Embolization Device with Shield Technology™ is the first listed.
NCT04391803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04391803 about?
NCT04391803 is a clinical study titled "EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)". The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
What is the current status of trial NCT04391803?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2022-05-06. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT04391803?
The interventions under investigation include: Pipeline™ Flex Embolization Device with Shield Technology™ (DEVICE).
Who is sponsoring clinical trial NCT04391803?
This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.